Overactive Bladder (OAB)

Highly prevalent and disabling health disorder.

Overactive bladder (OAB) is a severe chronic condition that can negatively impact patients’ quality of life. OAB is characterized by symptoms such as urgency, frequency, and incontinence when voiding urine. Moreover, patients who wake up more than two times per night to urinate are diagnosed as suffering from nocturia, which is another common symptom of OAB that disrupts the sleep cycle. As a result of chronic sleep deprivation, OAB causes fatigue, memory deficits, depression, embarrassment, increased risks of illnesses, and accidents. These conditions are highly debilitating and disturbing to the patient’s personal and social life, preventing them from going to work or performing very basic tasks such as going to the supermarket.

Prevalence increases significantly with age.

OAB is common, especially as you age, and affects around 15 -20% of women over the age of 40. OAB is associated with a yearly healthcare cost of 4-5 billion. There are currently available treatments, however, these have serious side effects. Around 70-90% of patients discontinue the available treatments because of their side effects. Side effects experienced include constipation, dry mouth, and sometimes even tachycardia and palpitations.

OAB is thought to affect around 15 -20% of women over the age of 40 years. It has a huge impact on quality of life: sleep deprivation, fatigue, memory lapses, embarrassment.


Inura’s first-of-a-kind urethral suppository.

We have developed a proprietary technology that allows the local delivery of therapeutic agents to the urinary tract. It consists of a simple, patient-friendly method of local treatment with a urethral suppository of oxybutynin for Overactive Bladder. 

The suppository contains a lower drug dose as it acts at the site of action and is less systemically absorbed diluted by the bloodstream, thereby decreasing the systemic side effects.

Inura’s product has the potential to revolutionize patient’s quality of life that are suffering from this condition. This technology will allow them to dramatically change the way they cope with their health disorder and gain back control in their lives.

 Local administration, limited side effects.

Our technology is a patented female urethral suppository that distributes an active pharmaceutical ingredient (API) directly to the surrounding tissues for rapid action. The first product contains oxybutynin, which has been in use for decades either as oral or transdermal therapy.  The treatment is expected to provide quick relief lasting up to 6-8 hours (i.e. a full night of sleep) with no or very limited side-effects owed in particular to the drug being delivered locally.

Clear benefits

Suppository with unique features & superior design to fit the female urethra and facilitate easy administration.

Solution for Overactive bladder (OAB).

Competitive pricing compared to generics possible due to the use of off-patent oxybutynin.

Local, urethral administration

Limited side effects


Existing market

The need for new, innovative therapies is evident. There is an existing market for these conditions generating annual sales over CHF 3 billion by several pharmaceutical manufacturers. Inura performed a market research study, where physicians were interviewed about this novel suppository. The results of the questionnaire showed that physicians would prescribe this novel solution.

Market drivers

For the development and growth of Inura we consider 3 major market drivers:

  • Greater therapeutic efficacy because of our route of administration
  • Reduced side effects because the drug is delivered locally
  • Competitive price compared to other available reimbursed therapies

Development Plan







IP Consultant



Office address

Inura Medical AG
c/o HEMEX Incubator
Kasernenstrasse 30 | 4410 Liestal | Switzerland 

E-Mail addresses

Inura Medical AG

Telephone contact

Mo-Fri 09:00-18:00 CET, our office can be reached under (+41) 61-927-28-09.